Страна: САЩ
Език: английски
Източник: NLM (National Library of Medicine)
LEVOCARNITINE HYDROCHLORIDE (UNII: J3Y5E6IKS3) (LEVOCARNITINE - UNII:0G389FZZ9M)
Lake Erie Medical DBA Quality Care Products LLC
LEVOCARNITINE HYDROCHLORIDE
LEVOCARNITINE HYDROCHLORIDE 5 mg
PRESCRIPTION DRUG
New Drug Application
XYZAL - LEVOCETIRIZINE DIHYDROCHLORIDE TABLET, FILM COATED LAKE ERIE MEDICAL DBA QUALITY CARE PRODUCTS LLC ---------- XYZAL 5 MG 11 DESCRIPTION Levocetirizine dihydrochloride, the active component of XYZAL tablets and oral solution, is an orally active H - receptor antagonist. The chemical name is (R)-[2-[4-[(4-chlorophenyl) phenylmethyl]-1- piperazinyl] ethoxy] acetic acid dihydrochloride. Levocetirizine dihydrochloride is the R enantiomer of cetirizine hydrochloride, a racemic compound with antihistaminic properties. The empirical formula of levocetirizine dihydrochloride is C H ClN O •2HCl. Enter section text here 1 INDICATIONS AND USAGE 1.1 Allergic Rhinitis XYZAL is indicated for the relief of symptoms associated with allergic rhinitis (seasonal and perennial) in adults and children 6 years of age and older. 1.2 Chronic Idiopathic Urticaria XYZAL is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. 4 CONTRAINDICATIONSThe use of XYZAL is contraindicated in: Patients with known hypersensitivity to levocetirizine or any of the ingredients of XYZAL, or to cetirizine. Observed reactions range from urticaria to anaphylaxis [see _Adverse Reactions (6.2)_]. 6 ADVERSE REACTIONS Use of XYZAL has been associated with somnolence, fatigue, and asthenia [see _Warnings and_ _Precautions (5.1)_]. 6.1 Clinical Trials Experience The safety data described below reflect exposure to XYZAL in 2549 patients with seasonal or perennial allergic rhinitis and chronic idiopathic urticaria in 12 controlled clinical trials of 1 week to 6 months duration. The short-term (exposure up to 6 weeks) safety data for adults and adolescents are based upon eight clinical trials in which 1896 patients (825 males and 1071 females aged 12 years and older) were treated with XYZAL 2.5, 5, or 10 mg once daily in the evening. The short-term safety data from pediatric patients are based upon two clinical trials in which 243 children with seasonal or peren Прочетете целия документ